(UroToday.com) Dr. Laurence Albiges provided a discussion of two clinical studies, one from the COSMIC-021 trial examining combination cabozantinib and atezolizumab in untreated metastatic clear cell renal cell carcinoma, and the other an RNA expression biomarker-driven trial of tyrosine kinase inhibitor versus nivolumab monotherapy versus nivolumab and ipilimumab.